Cargando…

Longitudinal Connectomes as a Candidate Progression Marker for Prodromal Parkinson’s Disease

Parkinson’s disease is the second most prevalent neurodegenerative disorder in the Western world. It is estimated that the neuronal loss related to Parkinson’s disease precedes the clinical diagnosis by more than 10 years (prodromal phase) which leads to a subtle decline that translates into non-spe...

Descripción completa

Detalles Bibliográficos
Autores principales: Peña-Nogales, Óscar, Ellmore, Timothy M., de Luis-García, Rodrigo, Suescun, Jessika, Schiess, Mya C., Giancardo, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333847/
https://www.ncbi.nlm.nih.gov/pubmed/30686966
http://dx.doi.org/10.3389/fnins.2018.00967
_version_ 1783387631642476544
author Peña-Nogales, Óscar
Ellmore, Timothy M.
de Luis-García, Rodrigo
Suescun, Jessika
Schiess, Mya C.
Giancardo, Luca
author_facet Peña-Nogales, Óscar
Ellmore, Timothy M.
de Luis-García, Rodrigo
Suescun, Jessika
Schiess, Mya C.
Giancardo, Luca
author_sort Peña-Nogales, Óscar
collection PubMed
description Parkinson’s disease is the second most prevalent neurodegenerative disorder in the Western world. It is estimated that the neuronal loss related to Parkinson’s disease precedes the clinical diagnosis by more than 10 years (prodromal phase) which leads to a subtle decline that translates into non-specific clinical signs and symptoms. By leveraging diffusion magnetic resonance imaging brain (MRI) data evaluated longitudinally, at least at two different time points, we have the opportunity of detecting and measuring brain changes early on in the neurodegenerative process, thereby allowing early detection and monitoring that can enable development and testing of disease modifying therapies. In this study, we were able to define a longitudinal degenerative Parkinson’s disease progression pattern using diffusion magnetic resonance imaging connectivity information. Such pattern was discovered using a de novo early Parkinson’s disease cohort (n = 21), and a cohort of Controls (n = 30). Afterward, it was tested in a cohort at high risk of being in the Parkinson’s disease prodromal phase (n = 16). This progression pattern was numerically quantified with a longitudinal brain connectome progression score. This score is generated by an interpretable machine learning (ML) algorithm trained, with cross-validation, on the longitudinal connectivity information of Parkinson’s disease and Control groups computed on a nigrostriatal pathway-specific parcellation atlas. Experiments indicated that the longitudinal brain connectome progression score was able to discriminate between the progression of Parkinson’s disease and Control groups with an area under the receiver operating curve of 0.89 [confidence interval (CI): 0.81–0.96] and discriminate the progression of the High Risk Prodromal and Control groups with an area under the curve of 0.76 [CI: 0.66–0.92]. In these same subjects, common motor and cognitive clinical scores used in Parkinson’s disease research showed little or no discriminative ability when evaluated longitudinally. Results suggest that it is possible to quantify neurodegenerative patterns of progression in the prodromal phase with longitudinal diffusion magnetic resonance imaging connectivity data and use these image-based patterns as progression markers for neurodegeneration.
format Online
Article
Text
id pubmed-6333847
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63338472019-01-25 Longitudinal Connectomes as a Candidate Progression Marker for Prodromal Parkinson’s Disease Peña-Nogales, Óscar Ellmore, Timothy M. de Luis-García, Rodrigo Suescun, Jessika Schiess, Mya C. Giancardo, Luca Front Neurosci Neuroscience Parkinson’s disease is the second most prevalent neurodegenerative disorder in the Western world. It is estimated that the neuronal loss related to Parkinson’s disease precedes the clinical diagnosis by more than 10 years (prodromal phase) which leads to a subtle decline that translates into non-specific clinical signs and symptoms. By leveraging diffusion magnetic resonance imaging brain (MRI) data evaluated longitudinally, at least at two different time points, we have the opportunity of detecting and measuring brain changes early on in the neurodegenerative process, thereby allowing early detection and monitoring that can enable development and testing of disease modifying therapies. In this study, we were able to define a longitudinal degenerative Parkinson’s disease progression pattern using diffusion magnetic resonance imaging connectivity information. Such pattern was discovered using a de novo early Parkinson’s disease cohort (n = 21), and a cohort of Controls (n = 30). Afterward, it was tested in a cohort at high risk of being in the Parkinson’s disease prodromal phase (n = 16). This progression pattern was numerically quantified with a longitudinal brain connectome progression score. This score is generated by an interpretable machine learning (ML) algorithm trained, with cross-validation, on the longitudinal connectivity information of Parkinson’s disease and Control groups computed on a nigrostriatal pathway-specific parcellation atlas. Experiments indicated that the longitudinal brain connectome progression score was able to discriminate between the progression of Parkinson’s disease and Control groups with an area under the receiver operating curve of 0.89 [confidence interval (CI): 0.81–0.96] and discriminate the progression of the High Risk Prodromal and Control groups with an area under the curve of 0.76 [CI: 0.66–0.92]. In these same subjects, common motor and cognitive clinical scores used in Parkinson’s disease research showed little or no discriminative ability when evaluated longitudinally. Results suggest that it is possible to quantify neurodegenerative patterns of progression in the prodromal phase with longitudinal diffusion magnetic resonance imaging connectivity data and use these image-based patterns as progression markers for neurodegeneration. Frontiers Media S.A. 2019-01-09 /pmc/articles/PMC6333847/ /pubmed/30686966 http://dx.doi.org/10.3389/fnins.2018.00967 Text en Copyright © 2019 Peña-Nogales, Ellmore, de Luis-García, Suescun, Schiess and Giancardo. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Peña-Nogales, Óscar
Ellmore, Timothy M.
de Luis-García, Rodrigo
Suescun, Jessika
Schiess, Mya C.
Giancardo, Luca
Longitudinal Connectomes as a Candidate Progression Marker for Prodromal Parkinson’s Disease
title Longitudinal Connectomes as a Candidate Progression Marker for Prodromal Parkinson’s Disease
title_full Longitudinal Connectomes as a Candidate Progression Marker for Prodromal Parkinson’s Disease
title_fullStr Longitudinal Connectomes as a Candidate Progression Marker for Prodromal Parkinson’s Disease
title_full_unstemmed Longitudinal Connectomes as a Candidate Progression Marker for Prodromal Parkinson’s Disease
title_short Longitudinal Connectomes as a Candidate Progression Marker for Prodromal Parkinson’s Disease
title_sort longitudinal connectomes as a candidate progression marker for prodromal parkinson’s disease
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333847/
https://www.ncbi.nlm.nih.gov/pubmed/30686966
http://dx.doi.org/10.3389/fnins.2018.00967
work_keys_str_mv AT penanogalesoscar longitudinalconnectomesasacandidateprogressionmarkerforprodromalparkinsonsdisease
AT ellmoretimothym longitudinalconnectomesasacandidateprogressionmarkerforprodromalparkinsonsdisease
AT deluisgarciarodrigo longitudinalconnectomesasacandidateprogressionmarkerforprodromalparkinsonsdisease
AT suescunjessika longitudinalconnectomesasacandidateprogressionmarkerforprodromalparkinsonsdisease
AT schiessmyac longitudinalconnectomesasacandidateprogressionmarkerforprodromalparkinsonsdisease
AT giancardoluca longitudinalconnectomesasacandidateprogressionmarkerforprodromalparkinsonsdisease